Regeneus surges on back of Progenza patent news
Finfeed
Archived
Mar 23, 2020
The US Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for clinical-stage regenerative medicine company Regeneus Ltd's (ASX: RGS) lead stem cell platform technology Progenza.
